Diversify Advisory Services LLC acquired a new position in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 33,706 shares of the pharmacy operator's stock, valued at approximately $3,609,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Gables Capital Management Inc. bought a new position in shares of CVS Health in the 2nd quarter worth $52,000. Wealthfront Advisers LLC bought a new position in CVS Health in the second quarter worth about $19,660,000. Foster & Motley Inc. bought a new stake in shares of CVS Health in the 2nd quarter valued at about $1,833,000. Main Street Financial Solutions LLC raised its stake in shares of CVS Health by 23.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 3,890 shares of the pharmacy operator's stock worth $402,000 after acquiring an additional 750 shares in the last quarter. Finally, Alamar Capital Management LLC acquired a new stake in CVS Health in the second quarter valued at approximately $391,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently issued reports on CVS. Wall Street Zen raised CVS Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Truist Financial increased their price target on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Royal Bank Of Canada raised their price target on CVS Health from $107.00 to $113.00 and gave the stock an "outperform" rating in a report on Thursday, July 9th. Bank of America upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a report on Monday, June 22nd. Finally, Barclays increased their price objective on shares of CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Twenty-two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $106.75.
Check Out Our Latest Research Report on CVS Health
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS reported strong second-quarter results, with earnings per share rising more than 40% year over year as profitability in its Health Care Benefits segment improved. The company also raised its 2026 adjusted operating income outlook, reinforcing the recovery story. CVS Q2 EPS Gains From Improved Health Care Benefits Profitability
- Positive Sentiment: CVS appointed Teresa Heitsenrether, JPMorgan’s data and analytics chief, to its board. Her technology, analytics and operating experience could support CVS’s artificial-intelligence and data initiatives, potentially improving efficiency and decision-making across its businesses. CVS adds JPMorgan data executive to board amid AI push
- Positive Sentiment: Brokerages assigned CVS an average “Moderate Buy” rating, reflecting improved earnings momentum and optimism about Aetna’s performance. CVS Health Given Average Rating of Moderate Buy
Insider Transactions at CVS Health
In other CVS Health news, Director Larry Robbins sold 370,462 shares of the firm's stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares of the company's stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.85% of the company's stock.
CVS Health Stock Performance
Shares of CVS stock opened at $94.87 on Wednesday. The business has a fifty day moving average of $102.41 and a 200 day moving average of $88.56. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $121.33 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61.
CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company's quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, research analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.
CVS Health Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health's dividend payout ratio is 70.37%.
About CVS Health
(
Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
